Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) SVP Sells 2,000 Shares of Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,860,920.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $3.02 during midday trading on Monday, hitting $604.12. The company’s stock had a trading volume of 1,228,281 shares, compared to its average volume of 1,564,947. The stock’s 50-day moving average price is $563.01 and its 200-day moving average price is $565.97. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $230.60 billion, a PE ratio of 38.75, a price-to-earnings-growth ratio of 2.83 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $614.65.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.15 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of large investors have recently added to or reduced their stakes in TMO. IFG Advisory LLC bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $220,000. Blue Trust Inc. boosted its position in Thermo Fisher Scientific by 6.0% during the fourth quarter. Blue Trust Inc. now owns 851 shares of the medical research company’s stock worth $430,000 after purchasing an additional 48 shares during the period. Opal Wealth Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 5.7% during the fourth quarter. Opal Wealth Advisors LLC now owns 804 shares of the medical research company’s stock worth $427,000 after buying an additional 43 shares during the last quarter. Bensler LLC lifted its holdings in shares of Thermo Fisher Scientific by 15.5% during the fourth quarter. Bensler LLC now owns 6,910 shares of the medical research company’s stock worth $3,668,000 after buying an additional 928 shares during the last quarter. Finally, Palumbo Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 10.9% during the fourth quarter. Palumbo Wealth Management LLC now owns 2,782 shares of the medical research company’s stock worth $1,477,000 after buying an additional 274 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of several analyst reports. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Jefferies Financial Group reissued a “buy” rating and set a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a report on Monday, June 3rd. Raymond James boosted their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $618.94.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.